Key Takeaways:
- The round comes as mounting evidence connects the gut microbiome to immune health, metabolism, and chronic disease.
- The platform serves nearly 200,000 customers and more than 6,000 healthcare practitioners.
- Tiny Health is committing $5 million to advance microbiome science and support research.
Tiny Health, a company pioneering gut microbiome intelligence, raised $33 million in Series B funding.
WHO: Founded in 2020 and launched in 2022, Austin, Texas–based Tiny Health introduced the first gut microbiome test for babies, built on shotgun metagenomic sequencing, alongside gut and vaginal microbiome testing for moms. The company is grounded in the science of the first 1,000 days of life, when the gut microbiome is most malleable and its influence on lifelong immune health and chronic conditions is most profound. Tiny Health’s proprietary dataset of nearly 200,000 microbiome profiles delivers personalized, science-backed guidance tied directly to a user's results.
Tiny Health owns its full, in-house bioinformatics pipeline. It is the only gut microbiome company that has published an interventional randomized controlled trial (RCT): a 2025 study in Pediatric Allergy and Immunology demonstrating that targeted microbiome interventions reduced infants’ odds of developing eczema by 83%.
WHY: Tiny Health will use the capital to advance clinical research and interventional studies, expand its healthcare practitioner education, and scale Powered by Tiny, its B2B platform.
IN THEIR OWN WORDS: “We founded Tiny Health because the science is so impactful, the need is urgent, and no one else was building for the whole lifespan,” said Cheryl Sew Hoy, CEO and founder of...
